亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Cardiac Tissue Derived Stem Cells (13079)

*Abstract

     

     

Features and Benefits

  • Unique subset of cardiac stem cells not previously identified.
  • May provide for new methods for regenerating and/or repairing damaged or poorly functional myocardium.
  • May allow for the generation of pharmaceutical compositions containing autologous stem cells.

      

*This Technology is available for licensing, further development, or industrial partnering*

     

Technology

     

Researchers at the University of Louisville have identified and isolated subpopulations of resident cardiac stem cells that are positive for markers of embryonic stem cells; do not express c-kit, CD34, or CD45; and are demonstrably different from previously identified cardiac stem cells, bone marrow mesenchymal stem cells (MSCs), and/or hematopoietic stem cells (HSCs). The researchers have also provided methods for isolating these subpopulations of cardiac stem cells from myocardium and uses of these cells and progeny cell populations expanded therefrom for heart and/or myocardial repair.

       

Markets Addressed

     

While care after heart injury has improved clinical outcomes, there still remains a need improved cardiac repair and regeneration. In recent years, there has been a paradigm shift in the dogma that the heart becomes terminally differentiated shortly after the neonatal period. This dogma has been overturned with the widely accepted discovery of not only dividing cardiomyocytes but also the discovery of resident stem cells contained within myocardial niches. It has been determined that this pool of stem cells is not made up of mobilized bone marrow cells, but are actual stem cells residing within the myocardial tissue itself. However, noting the plethora of varying phenotypes present within the myocardium, contributing to both functional and structural integrity of the organ, it is unlikely that this single population of c-kit+ cardiac stem cells is solely responsible for maintenance not only of homeostasis but also mounting response to myocardial injury.

     

Thus, there remains a need for additional compositions and methods which enable repair or regeneration of myocardium after injury. This technology may meet this need by providing for both additional stem-cell containing compositions as well as methods for the isolation and expansion thereof.

     

Technology Status

  • IP Status: International rights available
  • Development Status: Needs additional development
  • Fields of Use Available: All
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备